The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

 Dendreon Corp  (DNDN) Trade Now »     Rate DNDN  -  Discuss DNDN  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Biotechnology & Drugs
SocialPicks Sentiment:

** v.s. other stocks 		This Quarter's Sentiment:
All:
76.0%
Top:
75.0%
Rate DNDN:


Home
Analysis & Videos
Quotes
Bull or Bear
Discuss
        

DNDN: Bull or Bear? From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

BioMed News Bytes: CombinatoRx, Dendreon, Photocure, Pozen Graphic_rating_buy DNDN
Mikerun
73%

On 11/2/09, Dendreon (NASDAQ: DNDN) announced that it has completed the submission of its amended Biologics License Application (BLA) for PROVENGE (sipuleucel-T), seeking approval for men with metastatic castrate-resistant prostate cancer (CRPC). The amended BLA includes data from the IMPACT trial, which was conducted under a Special Protocol Assessment agreement with the FDA. The IMPACT study met its pre-specified primary endpoint demonstrating a statistically significant improvement in overall survival in men with metastatic CRPC.

<> PROVENGE is currently available through several ong...
By  Mike Havrilla   (+1.04%  risk: conservative)  11/20/09 Comment


New Global Equity Index to Track Immunotherapy, Vaccine Stocks Graphic_rating_buy DNDN
Mikerun
73%
Earlier this week, Dendreon (NASDAQ: DNDN ) announced that it has completed the submission of its amended Biologics License Application ( BLA ) for PROVENGE (sipuleucel-T), seeking approval for men with metastatic castrate-resistant prostate cancer ( CRPC ). The amended BLA includes data from the IMPACT trial, which was conducted under a Special Protocol Assessment agreement with the FDA. The IMPACT study met its pre-specified primary endpoint demonstrating a statistically significant improvement in overall survival in men with metastatic CRPC.
 
<> PROVENGE is currently ava...
By  Mike Havrilla   (+1.04%  risk: conservative)  11/04/09 Comment


New Stock Indexes to Track Trends in Healthcare Sector Graphic_rating_buy DNDN
Mikerun
73%

Coming Soon. . . a premium service offered in collaboration with Investars YOU for full access to a global database of over 1,000 stocks which are organized and managed within my 20 ProActive HavRx stock indexes . The expected pricing for premium access is $60 per year and will include full access to all of the component stocks in the indexes and tracking data for the indexes. 

<> Emerging Cancer Diagnostic / Therapeutic (Dx / Tx) Index

The actively managed HavRx Emerging Cancer Dx / Tx Index constituents reflect a cross-section of emerging cancer companies with <><><><><><><><><><><><><><><><><><><>< />< /><><>< />< /><><>< />< />< />< /><><>< />< /><><>< />< /><><>< />< /><><><><><><><><><><>< />< /><><>< />< />< />< /><><>< />< /><><>< />< /><><>< />< />< />< /><><>< />< />< />< /><><>< />< />< />< /><><>< />< /><><><><><><><><><>...
By  Mike Havrilla   (+1.04%  risk: conservative)  10/28/09 Comment


Quantum Immunologics: Developing Universal Therapeutic Cancer Vaccine Graphic_rating_buy DNDN
Mikerun
73%
<> <> Quantum Immunologics (QI) (privately held) is dedicated to improving the treatment outcome and quality of life for cancer patients through the research, development, and production of innovative therapeutic and diagnostic products that are based on the universal cancer antigen (oncofetal antigen or OFA). Quantum’s integrated approach to the treatment, diagnosis, and monitoring of cancer is being developed to create novel, individualized products and services that offer a greatly reduced cost, a high rate of efficacy, and minimal side effects compared to conventional treatments such as ra<><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>...
By  Mike Havrilla   (+1.04%  risk: conservative)  10/25/09 Comment


ImmunoCellular (OTC: IMUC.OB): Top Gainer in Cancer Immunotherapy Index Graphic_rating_buy DNDN
Mikerun
73%
<> The Mentor Capital Cancer Immunotherapy (CI) Index of 10 leading cancer immunotherapy stocks has increased 58% in its first two months of reporting. The CI Index gain was paced by the 233% share price improvement of ImmunoCellular Theraputics, Inc. (OTC: IMUC.OB) under the leadership of CEO Manish Singh, PhD. The increased interest in the immunotherapy companies and growth of the sector followed the positive Phase 3 results of Dendreon (NASDAQ: DNDN), a CI Index component company, for its prostate cancer product Provenge and resulting 1,000% share price improvement during the Spring of 200...
By  Mike Havrilla   (+1.04%  risk: conservative)  09/16/09 Comment



ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 21.10 +34.25% 381
2 Gerald Greene 18.14 +72.34% 210
3 stockmarketfunding.com 17.66 +25.65% 55
4 akiralegrand 13.47 +14.32% 61
5 anup2104 12.13 +76.91% 39


POPULAR STOCKS
Symbol Company Name Sentiment
EBAY eBay Inc
XOM Exxon Mobil Corp
JNJ Johnson & Johnson
AAPL Apple Computer Inc
T AT&T Inc
MO Altria Group Inc

TODAY'S HEADLINES

TODAY'S TOP PICKS

 

StreetInsider.com on DNDN

Visit streetinsider.com


Discussion Wall + Add  
tanumoy   (+110.44%  risk: conservative)
Upcoming data of an Alzheimer's drug to be presente.. - A small cap company is going to be presenting data on their Alzheimer's drug at the Alzheimer's conference in July. If the trials data is positive, it...
+   0 replies


More Resources

Graphic_arrow1 About Dendreon Corp - Answers.com

Graphic_arrow1 Historical Prices - Yahoo

Graphic_arrow1 Message Boards - BoardCentral.com

Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch